C-reactive protein: A predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study

Gut

Volumn 57, Issue 11, 2008, Pages 1518-1523

  Henriksen, M ^a,h   Jahnsen, J ^b   Lygren, I ^c   Stray, N ^d   Sauar, J ^e   Vatn, M H ^f   Mourn, B ^b,g  

^a Østfold Hospital   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d DIAKONHJEMMET HOSPITAL   (Norway)

^e TELEMARK HOSPITAL   (Norway)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF OSLO   (Norway)

^h Østfold Hospital Moss   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CIGARETTE SMOKING; CROHN DISEASE; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; INTESTINE RESECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 54349117795     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.146357     Document Type: Article

References (25)

1. Darlington GJ, Wilson DR, Lachman LB. Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J Cell Biol 1986;103:787-93.
2. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006;130:650-6.
3. Moum B, Vatn MH, Ekbom A, et al. Incidence of inflammatory bowel disease in southeastern Norway: evaluation of methods after 1 year of registration. Southeastern Norway IBD Study Group of Gastroenterologists. Digestion 1995;56:377-81.
4. Henriksen M, Jahnsen J, Lygren I, et al. Change of diagnosis during the first five years after onset of inflammatory bowel disease: Results of a prospective follow-up study (the IBSEN Study). Scand J Gastroenterol 2006;41:1037-43.
5. Gesche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.
6. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation-and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002;14:409-12.
7. Shine B, Berghouse L, Jones JE, et al. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 1985;148:105-9.
8. Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995;73:354-5.
9. Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982;12:351-9.
10. Pepys MB, Druguet M, Klass HJ, et al. Immunological studies in inflammatory bowel disease. Ciba Found Symp 1977;46:283-304.
11. Saverymuttu SH, Hodgson HJ, Chadwick VS, et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986;27:809-13.
12. Gross V, Andus T, Caesar I, et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992;102:514-9.
13. Greenfield JR, Samaras K, Jenkins AB, et al. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation 2004;109:3022-8.
14. Rawson ES, Freedson PS, Osganian SK, et al. Body mass index, but not physical activity, is associated with C-reactive protein. Med Sci Sports Exerc 2003;35:1160-6.
15. Maachi M, Pieroni L, Bruckert E, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 2004;28:993-7.
16. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999;117:73-81.
17. Colombel JF, Solem CA, Sandborn WJ, et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 2006;55:1561-7.
18. Florin TH, Paterson EW, Fowler EV, et al. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol 2006;41:306-11.
19. Solem CA, Loftus Jr EV, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707-12.
20. Moran A, Jones A, Asquith P. Laboratory markers of colonoscopic activity in ulcerative colitis and Crohn's colitis. Scand J Gastroenterol 1995;30:356-60.
21. Gomes P, du Boulay C, Smith CL, et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986;27:92-5.
22. Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988;10:401-5.
23. Consigny Y, Modigliani R, Colombel JF, et al. Biological markers of short term relapse in Crohn's disease (CD). Gastroenterology 2001;20(Suppl):A53.
24. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-8.
25. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10.